Merck KGaA (FRA:MRK) has been given a consensus recommendation of “Hold” by the twenty-one ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, fifteen have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is €101.10 ($117.56).
Several equities research analysts recently weighed in on MRK shares. Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the company a “buy” rating in a report on Thursday, January 24th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “buy” rating in a report on Tuesday, February 5th. UBS Group set a €115.00 ($133.72) price objective on Merck KGaA and gave the company a “buy” rating in a report on Thursday, March 7th. Finally, Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA and gave the company a “buy” rating in a report on Friday, March 8th.
Shares of FRA MRK traded down €1.04 ($1.21) during mid-day trading on Friday, hitting €91.10 ($105.93). 989,909 shares of the stock traded hands. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Story: Swap
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.